🎉 M&A multiples are live!
Check it out!

Paradigm Biopharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Paradigm Biopharma and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Paradigm Biopharma Overview

About Paradigm Biopharma

Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.


Founded

2014

HQ

Australia
Employees

50

Financials

LTM Revenue $0.8M

LTM EBITDA -$27.2M

EV

$60.4M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Paradigm Biopharma Financials

Paradigm Biopharma has a last 12-month revenue of $0.8M and a last 12-month EBITDA of -$27.2M.

In the most recent fiscal year, Paradigm Biopharma achieved revenue of $41K and an EBITDA of -$36.8M.

Paradigm Biopharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Paradigm Biopharma valuation multiples based on analyst estimates

Paradigm Biopharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $29K $41K XXX XXX XXX
Gross Profit -$41K $18K XXX XXX XXX
Gross Margin -138% 42% XXX XXX XXX
EBITDA -$32.6M -$36.8M XXX XXX XXX
EBITDA Margin -110979% -88894% XXX XXX XXX
Net Profit -$24.7M -$32.6M XXX XXX XXX
Net Margin -83938% -78891% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Paradigm Biopharma Stock Performance

As of April 15, 2025, Paradigm Biopharma's stock price is AUD 0 (or $0).

Paradigm Biopharma has current market cap of AUD 121M (or $75.9M), and EV of AUD 96.1M (or $60.4M).

See Paradigm Biopharma trading valuation data

Paradigm Biopharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$60.4M $75.9M XXX XXX XXX XXX $-0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Paradigm Biopharma Valuation Multiples

As of April 15, 2025, Paradigm Biopharma has market cap of $75.9M and EV of $60.4M.

Paradigm Biopharma's trades at 80.0x LTM EV/Revenue multiple, and -2.2x LTM EBITDA.

Analysts estimate Paradigm Biopharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Paradigm Biopharma and 10K+ public comps

Paradigm Biopharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $60.4M XXX XXX XXX
EV/Revenue 122.8x XXX XXX XXX
EV/EBITDA -2.0x XXX XXX XXX
P/E -2.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Paradigm Biopharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Paradigm Biopharma Valuation Multiples

Paradigm Biopharma's NTM/LTM revenue growth is -74%

Paradigm Biopharma's revenue per employee for the last fiscal year averaged $1K, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Paradigm Biopharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Paradigm Biopharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Paradigm Biopharma and other 10K+ public comps

Paradigm Biopharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 41% XXX XXX XXX XXX
EBITDA Margin -6246% XXX XXX XXX XXX
EBITDA Growth 13% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -6320% XXX XXX XXX XXX
Revenue per Employee $1K XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 9447% XXX XXX XXX XXX
R&D Expenses to Revenue 88653% XXX XXX XXX XXX
Opex to Revenue 99164% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Paradigm Biopharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Paradigm Biopharma M&A and Investment Activity

Paradigm Biopharma acquired  XXX companies to date.

Last acquisition by Paradigm Biopharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Paradigm Biopharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Paradigm Biopharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Paradigm Biopharma

When was Paradigm Biopharma founded? Paradigm Biopharma was founded in 2014.
Where is Paradigm Biopharma headquartered? Paradigm Biopharma is headquartered in Australia.
How many employees does Paradigm Biopharma have? As of today, Paradigm Biopharma has 50 employees.
Is Paradigm Biopharma publicy listed? Yes, Paradigm Biopharma is a public company listed on ASX.
What is the stock symbol of Paradigm Biopharma? Paradigm Biopharma trades under PAR ticker.
When did Paradigm Biopharma go public? Paradigm Biopharma went public in 2015.
Who are competitors of Paradigm Biopharma? Similar companies to Paradigm Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Paradigm Biopharma? Paradigm Biopharma's current market cap is $75.9M
What is the current revenue of Paradigm Biopharma? Paradigm Biopharma's last 12-month revenue is $0.8M.
What is the current EBITDA of Paradigm Biopharma? Paradigm Biopharma's last 12-month EBITDA is -$27.2M.
What is the current EV/Revenue multiple of Paradigm Biopharma? Current revenue multiple of Paradigm Biopharma is 80.0x.
What is the current EV/EBITDA multiple of Paradigm Biopharma? Current EBITDA multiple of Paradigm Biopharma is -2.2x.
What is the current revenue growth of Paradigm Biopharma? Paradigm Biopharma revenue growth between 2023 and 2024 was 41%.
Is Paradigm Biopharma profitable? Yes, Paradigm Biopharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.